Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation
| Status: | Recruiting |
|---|---|
| Conditions: | Smoking Cessation |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 6/3/2018 |
| Start Date: | February 1, 2017 |
| End Date: | June 2021 |
| Contact: | Kayla Hernandez, B.S. |
| Email: | kayla.hernandez@duke.edu |
| Phone: | 919-684-5460 |
Targeting Reward Dysfunction as a Mechanism to Improve Smoking Cessation
The goal of this study is to evaluate the effects of a smoking cessation intervention
combining behavioral treatment with low nicotine cigarettes on neuroimaging measures of
reward function and smoking cessation outcomes. The results of this study will provide
information about mechanisms contributing to smoking and smoking cessation and will help to
guide future treatment studies.
combining behavioral treatment with low nicotine cigarettes on neuroimaging measures of
reward function and smoking cessation outcomes. The results of this study will provide
information about mechanisms contributing to smoking and smoking cessation and will help to
guide future treatment studies.
Smokers who are interested in quitting will be randomly assigned to one of two treatment
conditions. In the BA +VLNC condition (n = 24) smokers will switch to smoking very low
nicotine cigarettes (VLNCs) while wearing a 21 mg/d nicotine patch for 5 weeks prior to their
quit date. They will also participate in weekly behavioral activation (BA) treatment
sessions. Smokers in the VLNC Only group (n = 24) will undergo the same pharmacological
pretreatment but will undergo standard counseling and health education instead of BA.
Following the quit date, both groups will receive standard nicotine replacement therapy. At
baseline and pre-quit, BOLD response to smoking and non-smoking rewards will be measured
using fMRI after 24 hr abstinence. Latency to relapse will serve as a continuous clinical
outcome measure.
conditions. In the BA +VLNC condition (n = 24) smokers will switch to smoking very low
nicotine cigarettes (VLNCs) while wearing a 21 mg/d nicotine patch for 5 weeks prior to their
quit date. They will also participate in weekly behavioral activation (BA) treatment
sessions. Smokers in the VLNC Only group (n = 24) will undergo the same pharmacological
pretreatment but will undergo standard counseling and health education instead of BA.
Following the quit date, both groups will receive standard nicotine replacement therapy. At
baseline and pre-quit, BOLD response to smoking and non-smoking rewards will be measured
using fMRI after 24 hr abstinence. Latency to relapse will serve as a continuous clinical
outcome measure.
Inclusion Criteria:
- generally healthy
- intact intellectual functioning (K-BIT2 >79)
- smoking at least 5 cigarettes per day
- expired CO concentration of at least 8 ppm or urinary cotinine > 100 ng/mL
- interested in quitting smoking
Exclusion Criteria:
- inability to attend all experimental sessions
- report of significant health problems
- use of psychoactive medications or current participation in psychotherapy
- current unstable psychiatric illness as assessed by clinical diagnostic interview
- suicidal ideation with plan or intent
- regular use of smokeless tobacco
- current alcohol or drug abuse
- use of illegal drugs (excluding marijuana) as measured by urine drug screen
- current use of nicotine replacement therapy or other smoking cessation treatment
- presence of contraindications for nicotine replacement therapy
- left-handed
- presence of conditions that would make MRI unsafe
- claustrophobia
- history of fainting
- pregnant, trying to become pregnant, or breastfeeding
We found this trial at
1
site
Duke Univ Med Ctr As a world-class academic and health care system, Duke Medicine strives...
Click here to add this to my saved trials
